natgillin/translations-raw huggingface dataset:
Administration of 14C-tipranavir to subjects (n = 8) that received 500 mg tipranavir with 200 mg ritonavir; twice daily dosed to steady-state demonstrated that most radioactivity (median 82.3%) was excreted in faeces, while only a median of 4.4% of the radioactive dose administered was recovered in urine.
Primjena 14C-tipranavira ispitanicima (n = 8) koji su primali 500 mg tipranavira s 200 mg ritonavira dvaput dnevno, dozirano do stanja ravnoteže, pokazala je da se većina radioaktivnosti (prosjek 82,3%) izlučuje stolicom, dok je prosječno samo 4,4% primijenjene radioaktivne doze nađeno u urinu.
Administration of 1500 mg lapatinib (a substrate for and weak inhibitor of CYP3A4 and P-gp and a potent inhibitor of BCRP) with 800 mg pazopanib resulted in an approximately 50 % to 60 % increase in mean pazopanib AUC(0-24) and Cmax compared to administration of 800 mg pazopanib alone.
U usporedbi sa samostalnom primjenom 800 mg pazopaniba, istovremena primjena 1500 mg lapatiniba (supstrat i slabi inhibitor CYP3A4 i P-gp i potentni inhibitor za BCRP) i 800 mg pazopaniba rezultirala je s povećanjem od oko 50% do 60% srednjih vrijednosti AUC(0-24) i Cmax za pazopanib.
Administration of 185 MBq of ioflupane (123I) results in an absorbed dose to the uterus of 3.0 mGy.
Uporaba 185 MBq ioflupana (123I) rezultira apsorbiranom dozom od 3,0 mGy za uterus.
Administration of 245 mg tenofovir disoproxil (as fumarate) every 48 hours can be used based on modelling of single-dose pharmacokinetic data in HIV negative and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring haemodialysis, but has not been confirmed in clinical studies.
Na temelju modela podataka o farmakokinetici jednokratnih doza u HIV negativnih ispitanika koji nisu bili zaraženi virusom hepatitisa B, a imali su oštećenje funkcije bubrega različitih stupnjeva, uključujući i bubrežnu bolest u završnoj fazi za koju je bila potrebna hemodijaliza, može se primjenjivati doza od 245 mg tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) svakih 48 sati, ali ona nije potvrđena u kliničkim ispitivanjima.
Administration of 325 mg (or equivalent) non-enteric coated acetylsalicylic acid, 30 minutes prior to Tecfidera, over 4 days of dosing, did not alter the pharmacokinetic profile of Tecfidera and reduced the occurrence and severity of flushing in a healthy volunteer study.
Primjena 325 mg (ili ekvivalenta) acetilsalicilatne kiseline bez acidorezistentne ovojnice, 30 minuta prije Tecfidere, kroz 4 dana doziranja, nije promijenila farmakokinetički profil Tecfidere, a smanjila je pojavu i težinu navale crvenila uz osjećaj vrućine u ispitivanju sa zdravim dobrovoljcima.
Administration of a dose of vaccine may produce swellings (diameter of up to 12 cm in ruminants and 4 cm in pigs) in most animals.
Primjena doze cjepiva može uzrokovati otekline (promjera do 12 cm u preživača i 4 cm u svinja) u većini životinja.
Administration of a dose of vaccine may produce swellings (diameter of up to 12 cm in ruminants and 4cm in pigs) in most animals.
Primjena doze cjepiva može uzrokovati otekline (promjera do 12 cm u preživača i 4 cm u svinja) u većini životinja.
Administration of a FVIII:C containing VWF preparation restores the FVIII:C level to normal immediately after the first infusion.
Primjena FVIII:C koji sadrži pripravak VWF ponovno uspostavlja normalnu razinu FVIII:C neposredno nakon prve infuzije.
Administration of a loading dose has not been studied in acute conditions such as status epilepticus.
Primjena udarne doze nije proučavana u akutnim stanjima kao što je status epilepticus.
Administration of a loading dose has not been studied in patients with status epilepticus
Primjena udarne doze nije ispitivana u bolesnika s epileptičnim statusom.
Administration of a loading dose has not been studied in patients with status epilepticus.
Primjena udarne doze nije ispitivana u bolesnika s epileptičnim statusom.
Administration of a local anaesthetic medicinal product prior to injection of Xiapex into a Dupuytren’s cord is not recommended, as it may interfere with proper placement of the injection.
Ne preporučuje se primjena lokalnog anestetika prije injiciranja Xiapexa u Dupuytrenov tračak, jer bi mogao omesti pravilno uvođenje injekcije.
Administration of a pazopanib 400 mg crushed tablet increased AUC(0-72) by 46 % and Cmax by approximately 2 fold and decreased tmax by approximately 2 hours compared to administration of the whole tablet.
U usporedbi s primjenom cijele tablete, primjena 400 mg pazopaniba u obliku izmrvljene tablete povećala je AUC(0-72) za 46% i Cmax približno 2 puta i smanjilo tmax za približno 2 sata.
Administration of a second 5 g dose of Praxbind may be considered in the following situations:
Primjena druge doze Praxbinda od 5 g se može razmotriti u sljedećim situacijama:
Administration of a single 25 mg dose of eltrombopag as powder for oral suspension with a high- calcium, moderate fat and moderate calorie meal reduced plasma eltrombopag mean AUC0-∞ by 75% and mean Cmax by 79%.
Primjena jedne doze od 25 mg eltrombopaga u obliku praška za oralnu suspenziju uz obrok s visokim udjelom kalcija, umjerenim udjelom masnoća i umjerenom kalorijskom vrijednošću, smanjila je srednji plazmatski AUC0-∞ eltrombopaga za 75% i srednji Cmax za 79%.
Administration of a single 400/100 mg dose of Kaletra soft capsules with a moderate fat meal (500 – 682 kcal, 22.7 –25.1% from fat) was associated with a mean increase of 48% and 23% in lopinavir AUC and Cmax, respectively, relative to fasting.
Uzimanjem Kaletra mekih kapsula u jednokratnoj dozi od 400/100 mg uz obrok s umjerenim sadržajem masti (500 – 682 kcal, 22,7 –25,1% iz masnoća) AUC je porasla u prosjeku za 48%, a Cmax za 23% u odnosu na jednaku dozu uzetu natašte.
Administration of a single 400/100 mg dose of Kaletra tablets under fed conditions (high fat, 872 kcal, 56% from fat) compared to fasted state was associated with no significant changes in Cmax and AUCinf.
Primjena jedne 400/100 mg doze Kaletra tableta u uvjetima nakon obroka (hrana s visokim sadržajem masti, 872 kcal, 56% iz masti) u usporedbi sa stanjem na tašte nije pokazala značajne promjene u Cmax i AUCinf.
Administration of a single 400/100 mg dose of lopinavir/ritonavir tablets under fed conditions (high fat, 872 kcal, 56% from fat) compared to fasted state was associated with no significant changes in Cmax and AUCinf.
Primjena jedne 400/100 mg doze tableta lopinavira/ritonavira u uvjetima nakon obroka (hrana s visokim sadržajem masti, 872 kcal, 56% iz masti) u usporedbi sa stanjem na tašte nije pokazala značajne promjene u Cmax i AUCinf.
Administration of a single dose of parecoxib to lactating women following caesarean section resulted in the transfer of a relatively small amount of parecoxib and its active metabolite valdecoxib into human milk, and this resulted in a low relative dose for the infant (approximately 1% of the weight- adjusted maternal dose).
Primjena jedne doze parekoksiba u dojilja nakon carskog reza rezultirala je prijenosom relativno male količine parekoksiba i njegove djelatne tvari valdekoksiba u majčino mlijeko, što je rezultiralo malom relativnom dozom za dojenče (otprilike 1% doze u majki ponderirane prema težini).
Administration of a single dose of parecoxib to lactating women following caesarean section resulted in the transfer of a relatively small amount of parecoxib and its active metabolite valdecoxib into human milk, and this resulted in a low relative dose for the infant (approximately 1% of the weight- adjusted maternal dose).
Primjena jedne doze parekoksiba u dojilja nakon carskog reza rezultirala je prijenosom relativno male količine parekoksiba i njegovog aktivnog metabolita valdekoksiba u majčino mlijeko, što je rezultiralo malom relativnom dozom za dojenče (otprilike 1% doze u majki ponderirane prema težini).
Administration of a single oral dose of 300 mg aliskiren was associated with very minor changes in the pharmacokinetics of aliskiren (change in Cmax of less than 1.2 fold; increase in AUC of up to 1.6 fold) compared to matched healthy subjects.
Peroralna primjena jednokratne doze aliskirena od 300 mg bila je povezana s vrlo malim promjenama u farmakokinetici aliskirena (promjena Cmax–a za manje od 1,2 puta, povećanje AUC-a do najviše 1,6 puta) u usporedbi s usporedivim zdravim ispitanicima.
Administration of a two-fold overdose may be followed in most animals by a local reaction at the injection site.
Nakon predoziranja dvostrukom dozom kod većine životinja može doći do lokalne reakcije na mjestu ubrizgavanja.
Administration of a two-fold overdose may be followed in most animals by a local reaction at the injection site.
Nakon predoziranja dvostrukom količinom u većine životinja može doći do lokalne reakcije na mjestu ubrizgavanja.
Administration of ABILIFY solution for injection was well tolerated and produced no direct target organ toxicity in rats or monkeys after repeated dosing at systemic exposures (AUC) that were 15 and 5 times, respectively, human exposure at the maximum recommended human dose of 30 mg intramuscular.
Pimjena ABILIFY otopina za injekciju dobro se podnosila i nije imala nikakve izravne toksične učinke na ciljne organe u štakora i majmuna nakon ponovljene primjene i pri sistemskoj izloženosti (AUC) koja je u štakora bila 15 puta, a u majmuna 5 puta veća od izloženosti ljudi nakon maksimalne preporučene doze za ljude od 30 mg intramuskularno.
Administration of activated charcoal (powder made into a suspension) orally or via nasogastric tube (50 g every 6 hours for 24 hours) has been shown to reduce plasma concentrations of theactive metabolite A771726 by 37 % in 24 hours and by 48 % in 48 hours.
Primjenom aktivnog ugljena (prašak pripravljen kao suspenzija) oralno ili putem nazogastrične sonde (50 g svakih 6 sati tijekom 24 sata) smanjila se koncentracija aktivnog metabolita A771726 za 37 % u roku od 24 sata i za 48 % u roku od 48 sati.
Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance.
Primjena aktivnog ugljena također može pomoći pri uklanjanju neapsorbirane djelatne tvari.
Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance.
Za uklanjanje neapsorbirane djelatne tvari može se upotrijebiti i aktivni ugljen.
Administration of activated charcoal may also be used to aid in removal of unabsorbed rilpivirine hydrochloride.
Može se primijeniti i aktivni ugljen kako bi se pomoglo uklanjanju neapsorbiranog rilpivirinklorida.
Administration of activated charcoal may also be used to aid in removal of unabsorbed rilpivirine hydrochloride.
Također se može koristiti primjena aktivnog ugljena kako bi se pomoglo uklanjanje neapsorbiranog rilpivirinklorida.
Administration of activated charcoal may also be used to aid in the removal of unabsorbed active substance.
Može se primijeniti i aktivni ugljen kako bi se pridonijelo uklanjanju neapsorbirane djelatne tvari.
Administration of activated charcoal may be used to aid in removal of unabsorbed active substance.
Može se primijeniti aktivni ugljen kao pomoć u uklanjanju neapsorbirane djelatne tvari.
Administration of activated charcoal reduces apixaban exposure (see section 4.9).
Primjena aktivnog ugljena umanjuje izloženost apiksabanu (vidjeti dio 4.9).
Administration of adalimumab is not recommended during pregnancy.
Zbog toga se primjena adalimumaba u trudnica ne preporučuje.
Administration of Aerivio Spiromax to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Primjenu Airexar Spiromaxa u trudnica treba razmotriti samo ako je očekivana korist za majku veća od svakog mogućeg rizika za fetus.
Administration of Aldurazyme should be carried out in an appropriate clinical setting where resuscitation equipment to manage medical emergencies would be readily available.
Aldurazyme se mora primijeniti u odgovarajućem kliničkom okruženju s dostupnom opremom za reanimaciju za slučaj hitne medicinske intervencije.
Administration of ambrisentan to female rats from late-pregnancy through lactation caused adverse events on maternal behaviour, reduced pup survival and impairment of the reproductive capability of the offspring (with observation of small testes at necropsy), at exposure 3-fold the AUC at the maximum recommended human dose.
Primjena ambrisentana na ženkama štakora tijekom kasne trudnoće i laktacije uzrokovala je štetne događaje u vidu promjena u ponašanju majke, smanjenja preživljenja mladunčadi i poremećaja reproduktivne sposobnosti potomstva (uz nalaz smanjenih testisa na nekropsiji), pri izloženosti 3 puta AUC pri maksimalno preporučenoj dozi za ljude.
Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects (see section 4.5).
Ne preporučuje se istovremena primjena amlodopina s grejpom ili sokom od grejpa jer kod pojedinih bolesnika može doći do povećane bioraspoloživosti koja rezultira povećanim učinkom snižavanja krvnog tlaka (vidjeti dio 4.5).
Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects (see section 4.5).
Ne preporučuje se primjena amlodopina s grejpom ili sokom od grejpa jer kod pojedinih bolesnika može doći do povećane bioraspoloživosti koja rezultira povećanim učinkom snižavanja krvnog tlaka (vidjeti dio 4.5).
Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood  pressure lowering effects.
Ne preporučuje se primjena amlodipina s grejpom ili sokom od grejpa jer bi u nekih bolesnika moglo doći do povećanja bioraspoloživosti, što rezultira pojačanim  učinkom na snižavanje krvnog tlaka.
Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.
Ne preporučuje se primjena amlodipina s grejpom ili sokom od grejpa jer bi u nekih bolesnika moglo doći do povećanja bioraspoloživosti, što rezultira pojačanim učincima na snižavanje krvnog tlaka.
Administration of Amyvid and conduct of the procedure
Primjena lijeka Amyvid i provedba postupka
Administration of an anti-murine PDGFR- α surrogate antibody to pregnant mice during organogenesis at 50 and 150 mg/kg resulted in increased malformations (abnormal eyelid development) and skeletal alterations (frontal/parietal additional ossification site).
Primjena zamjenskog protutijela na mišji PDGFR-α u skotnih ženki miševa tijekom organogeneze u dozama od 50 i 150 mg/kg dovela je do povećanja malformacija (abnormalan razvoj očnih vjeđa) i skeletnih promjena (dodatno mjesto okoštavanja na frontalnoj/parijetalnoj kosti).
Administration of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) manufactured using a different process
Primjena cjepiva koja sadrže adjuvans AS03 i 3,75 µg HA dobivenog iz soja A/Vietnam/1194/2004 (H5N1), proizvedenog drugačijim postupkom proizvodnje
administration of Aptivus with
Istodobna se primjena ne
Administration of Axura is not recommended in patients with severe hepatic impairment.
Ne preporučuje se primjena Axure kod bolesnika s teškim oštećenjem jetrene funkcije.
Administration of Benlysta may result in hypersensitivity reactions and infusion reactions which can be severe, and fatal.
Primjena lijeka Benlysta može rezultirati reakcijama preosjetljivosti i infuzijskim reakcijama koje mogu biti teške, i opasne po život.
Administration of BUCCOLAM
Primjena BUCCOLAMA
Administration of capecitabine should be interrupted if treatment- related elevations in bilirubin of >3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of >2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina >3,0 x iznad gornje granice normale (GGN) ili jetrenih aminotransferaza (ALT, AST) >2,5 x iznad GGN.
Administration of capecitabine should be interrupted if treatment- related elevations in bilirubin of >3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of >2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina >3,0 x iznad gornje granice normale ili jetrenih aminotransferaza (ALT, AST) >2,5 x iznad gornje granice normale.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of >3.0 x ULN or treatment- related elevations in hepatic aminotransferases (ALT, AST) of >2.5 x ULN occur.
Primjenu kapecitabina treba prekinuti ako uzimanje lijeka izazove povećanje vrijednosti bilirubina >3,0 x iznad gornje granice normale ili jetrenih aminotransferaza (ALT, AST) >2,5 x iznad gornje granice normale.
administration of capsaicin should only be done under medical supervision
kapsaicin se smije primjenjivati samo pod medicinskim nadzorom
Administration of Cervarix at the same time as Twinrix has shown no clinically relevant interference in the antibody response to the HPV and hepatitis A antigens.
Istodobna primjena cjepiva Cervarix sa cjepivom Twinrix nije pokazala klinički relevantnu interferenciju u imunološkom odgovoru antitijela na HPV i hepatitis A antigene.
Administration of cinacalcet with food results in an approximate 50-80% increase in cinacalcet bioavailability.
Uzimanje sinakalceta s hranom povećava bioraspoloživost sinakalceta za oko 50 do 80 %.
Administration of clofarabine results in a rapid reduction in peripheral leukaemia cells.
Primjena klofarabina dovodi do brzog smanjenja broja leukemijskih stanica na periferiji.
Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect.
Primjena zdrobljene tablete s manjom količinom kašaste hrane ili tekućine ne bi trebala utjecati na farmakološku kvalitetu pa se ne očekuje niti promjena kliničkog učinka.
Administration of dabrafenib 150 mg twice daily and warfarin resulted in a decrease in AUC of S- and R- warfarin and of 37% and 33% compared to administration of warfarin alone.
Primjena dabrafeniba od 150 mg dvaput dnevno i varfarina rezultirala je smanjenjem AUC-a S- i R- varfarina od 37% odnosno 33% u usporedbi s primjenom samog varfarina.
Administration of Defitelio to patients who have haemodynamic instability, defined as inability to maintain mean arterial pressure with single pressor support, is not recommended.
Primjena lijeka Defitelio ne preporučuje se u bolesnika koji su hemodinamski nestabilni, a hemodinamska nestabilnost podrazumijeva nemogućnost održavanja prosječnog arterijskog tlaka pomoću jednog vazopresora.
Administration of dimethyl fumarate at oral doses of 25, 100, and 250 mg/kg/day to pregnant rats during the period of organogenesis resulted in maternal adverse effects at 4 times the recommended dose on an AUC basis, and low fetal weight and delayed ossification (metatarsals and hindlimb phalanges) at 11 times the recommended dose on an AUC basis.
Primjena dimetilfumarata u oralnim dozama od 25, 100 i 250 mg/kg/dan gravidnim štakoricama tijekom razdoblja organogeneze rezultirala je nuspojavama kod majke pri 4 puta preporučenoj dozi na temelju AUC i niskoj težini fetusa i usporenom okoštavanju (metatarzalne falange i falange stražnjih nogu) pri 11 puta preporučenoj dozi na temelju AUC.
Administration of emtricitabine/tenofovir disoproxil every 48 hours is recommended based on modelling of single-dose pharmacokinetic data for emtricitabine and tenofovir disoproxil in non-HIV infected subjects with varying degrees of renal impairment (see section 4.4).
Preporučuje se primjena emtricitabina/tenofovirdizoproksila svakih 48 sati, na temelju modeliranja farmakokinetičkih podataka za pojedinačne doze emtricitabina i tenofovirdizoproksila u ispitanika nezaraženih HIV-om, s različitim stupnjevima oštećenja bubrežne funkcije (vidjeti dio 4.4).
Administration of emtricitabine/tenofovir disoproxil with food resulted in a delay of approximately three quarters of an hour in reaching maximum tenofovir concentrations and increases in tenofovir AUC and Cmax of approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state.
Uzimanje emtricitabina/tenofovirdizoproksila s hranom rezultiralo je odgodom postizanja maksimalnih koncentracija tenofovira za približno tri četvrtine sata i porastom vrijednosti AUC i Cmax tenofovira za približno 35% odnosno 15%, kada se lijek uzimao s obrokom bogatim mastima ili s laganim obrokom, u usporedbi s uzimanjem natašte.
Administration of eptifibatide by intravenous bolus and infusion causes up to a 5-fold increase in bleeding time.
Davanje eptifibatida intravenskim bolusom i infuzijom uzrokuje produljenje vremena krvarenja do 5 puta.
Administration of eptifibatide is associated with an increase in major and minor bleeding as classified by the criteria of the TIMI study group.
Primjena eptifibatida je povezana s porastom broja velikih i manjih krvarenja klasificiranih prema TIMI kriterijima.
Administration of Esbriet with food results in a large reduction in Cmax (by 50%) and a smaller effect on AUC, compared to the fasted state.
Primjena lijeka Esbriet s hranom rezultira velikim smanjenjem Cmax (za 50%) i manjim učinkom na AUC u usporedbi s primjenom natašte.
Administration of eslicarbazepine acetate 1,200 mg once daily to female subjects using a combined oral contraceptive showed an average decrease of 37% and 42% in systemic exposure to levonorgestrel and ethinylestradiol, respectively, most likely caused by an induction of CYP3A4.
Primjena eslikarbazepinacetata 1200 mg jednom dnevno kod ženskih ispitanica koje koriste kombinirane oralne kontraceptive, pokazala je prosječno smanjenje od 37% u sistemskoj izloženosti levonorgestrelu i 42% u sistemskoj izloženosti etinilestradiolu, najvjerojatnije uzrokovano indukcijom CYP3A4.
administration of EVOTAZ with
EVOTAZ i sildenafila.
administration of EVOTAZ with
istodobna primjena lijeka EVOTAZ
ADMINISTRATION OF FOSCAN (96 hours prior to laser illumination of treatment site)
PRIMJENA FOSCANA (96 sati prije obasjavanja mjesta liječenja laserom)
Administration of Fuzeon to non-HIV-1 infected individuals may induce anti-enfuvirtide antibodies that cross-react with HIV gp41.
Primjena lijeka Fuzeon u osoba koje nisu zaražene virusom HIV-1 može potaknuti stvaranje anti- enfuvirtid protutijela koja imaju križnu reakciju s HIV gp41.
Administration of gefitinib once daily results in 2- to 8-fold accumulation, with steady-state exposures achieved after 7 to 10 doses.
Primjena gefitiniba jednom na dan dovodi do nakupljanja od 2 do 8 puta, a izloženost u stanju dinamičke ravnoteže postiže se nakon 7 do 10 doza.
Administration of Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe:
Primjena Ibandronic acid Accord 3 mg otopine za injekciju u napunjenoj štrcaljki:
Administration of IMBRUVICA with inducers of CYP3A4 can decrease ibrutinib plasma concentrations.
Primjena lijeka IMBRUVICA s induktorima CYP3A4 može smanjiti koncentracije ibrutiniba u plazmi.
Administration of immune globulins concomitantly with ProQuad may interfere with the expected immune response.
Imunoglobulini primijenjeni istodobno s cjepivom ProQuad mogu ometati očekivani imunološki odgovor.
Administration of Inflectra should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Ako bolesnik razvije novu ozbiljnu infekciju ili sepsu, treba prekinuti liječenje lijekom Inflectra i uvesti odgovarajuću antimikrobnu ili antimikotičku terapiju sve dok infekcija ne bude pod kontrolom.